TD Asset Management Inc. Sells 100,730 Shares of Merck & Co., Inc. (MRK)

Share on StockTwits

TD Asset Management Inc. decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,613,071 shares of the company’s stock after selling 100,730 shares during the quarter. TD Asset Management Inc. owned approximately 0.10% of Merck & Co., Inc. worth $185,372,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Prentiss Smith & Co. Inc. lifted its stake in Merck & Co., Inc. by 17.1% in the third quarter. Prentiss Smith & Co. Inc. now owns 4,793 shares of the company’s stock valued at $340,000 after acquiring an additional 700 shares during the last quarter. Boyd Watterson Asset Management LLC OH lifted its stake in Merck & Co., Inc. by 2.4% in the third quarter. Boyd Watterson Asset Management LLC OH now owns 31,345 shares of the company’s stock valued at $2,224,000 after acquiring an additional 725 shares during the last quarter. Sullivan Bruyette Speros & Blaney LLC lifted its stake in Merck & Co., Inc. by 4.9% in the third quarter. Sullivan Bruyette Speros & Blaney LLC now owns 16,310 shares of the company’s stock valued at $1,157,000 after acquiring an additional 756 shares during the last quarter. Institute for Wealth Management LLC. lifted its stake in Merck & Co., Inc. by 7.4% in the third quarter. Institute for Wealth Management LLC. now owns 11,084 shares of the company’s stock valued at $778,000 after acquiring an additional 759 shares during the last quarter. Finally, Chase Investment Counsel Corp lifted its stake in Merck & Co., Inc. by 14.7% in the third quarter. Chase Investment Counsel Corp now owns 5,933 shares of the company’s stock valued at $420,000 after acquiring an additional 762 shares during the last quarter. Institutional investors and hedge funds own 72.72% of the company’s stock.

In related news, insider Roger M. Perlmutter sold 225,443 shares of the firm’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $75.27, for a total transaction of $16,969,094.61. Following the transaction, the insider now directly owns 366,998 shares of the company’s stock, valued at $27,623,939.46. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Julie L. Gerberding sold 36,218 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $75.14, for a total transaction of $2,721,420.52. Following the transaction, the executive vice president now directly owns 82,481 shares in the company, valued at $6,197,622.34. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,279,104 shares of company stock worth $92,845,846. 0.32% of the stock is owned by insiders.

A number of research firms have recently issued reports on MRK. Wolfe Research began coverage on shares of Merck & Co., Inc. in a research note on Tuesday, October 23rd. They set an “outperform” rating for the company. BMO Capital Markets raised their target price on shares of Merck & Co., Inc. from $70.00 to $82.00 and gave the stock an “outperform” rating in a research note on Monday, October 22nd. ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research note on Wednesday, September 26th. Finally, Citigroup raised their target price on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $73.65.

NYSE MRK opened at $76.72 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.44 and a debt-to-equity ratio of 0.61. The stock has a market cap of $211.30 billion, a PE ratio of 19.28, a P/E/G ratio of 2.13 and a beta of 0.71. Merck & Co., Inc. has a 52-week low of $52.83 and a 52-week high of $80.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 25th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The company had revenue of $10.79 billion during the quarter, compared to analysts’ expectations of $10.87 billion. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%. As a group, equities research analysts expect that Merck & Co., Inc. will post 4.34 earnings per share for the current year.

Merck & Co., Inc. declared that its board has approved a share repurchase program on Thursday, October 25th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 5.1% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th. Investors of record on Monday, December 17th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.87%. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.48. The ex-dividend date is Friday, December 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 48.24%.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by BBNS and is owned by of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/12/08/td-asset-management-inc-sells-100730-shares-of-merck-co-inc-mrk/3065229.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Trading Strategy Methods and Types

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.